Literature DB >> 16786320

18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade.

Song-Mee Cho1, Yong Gyu Park, Joon Mo Lee, Jae Young Byun, Jae Mun Lee, Kyo-Young Lee, Gyeong-Sin Park, Hyeon-Sook Kim, Bae Young Lee, Kang-Hoon Lee, Kyung-Sup Song.   

Abstract

The aim of this study was to assess the correlation between 18F-fluorodeoxyglucose positron emission tomography (FDG PET) positivity of tumor recurrence and vascularity, Ki-67, p53, and histologic grade in patients with ovarian cancer. Nineteen patients with recurrent ovarian cancer underwent FDG PET before second-look surgery. Archival paraffin-embedded tissue materials were used to assess histologic grade including architectural pattern, mitotic activity, and nuclear pleomorphism; intratumor microvessel density (MVD); Ki-67; and p53. Univariate analysis was used to evaluate the correlation between FDG PET positivity and each biomarker. Stepwise logistic regression analysis was used to determine the best parameter to explain FDG PET positivity. MVD revealed significant positive correlation with FDG PET positivity (p=0.0341). There was no significant correlation between FDG PET positivity and Ki-67 or p53 (p=0.4040, p=0.6027). Mitotic activity yielded statistically significant positive correlations with FDG PET positivity (p=0.0448) although histologic grade revealed no positive correlation (p=1). Stepwise logistic regression analysis revealed MVD to be the strongest parameter for FDG PET positivity (OR=0.696, 95% CI 0.487-0.993, p=0.0458). In conclusion, FDG PET positivity revealed positive correlation with MVD and mitotic activity. MVD was the strongest parameter in predicting positive tumor recurrence on FDG PET.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786320     DOI: 10.1007/s00330-006-0326-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  37 in total

1.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

2.  Clinical relevance of imaging proliferative activity in lung nodules.

Authors:  Andreas K Buck; Martin Hetzel; Holger Schirrmeister; Gisela Halter; Peter Möller; Clemens Kratochwil; Andreas Wahl; Gerhard Glatting; Felix M Mottaghy; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-14       Impact factor: 9.236

3.  Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.

Authors:  Ukihide Tateishi; Hiroshi Nishihara; Eriko Tsukamoto; Toshiaki Morikawa; Nagara Tamaki; Kazuo Miyasaka
Journal:  J Comput Assist Tomogr       Date:  2002 Mar-Apr       Impact factor: 1.826

4.  Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts.

Authors:  F Kallinowski; K H Schlenger; S Runkel; M Kloes; M Stohrer; P Okunieff; P Vaupel
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

5.  Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.

Authors:  Tatsuo Torizuka; Shuji Nobezawa; Toshihiko Kanno; Masami Futatsubashi; Etsuji Yoshikawa; Hiroyuki Okada; Munetaka Takekuma; Makoto Maeda; Yasuomi Ouchi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-19       Impact factor: 9.236

6.  Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.

Authors:  B Y Karlan; R Hawkins; C Hoh; M Lee; N Tse; P Cane; J Glaspy
Journal:  Gynecol Oncol       Date:  1993-11       Impact factor: 5.482

7.  Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.

Authors:  Song-Mee Cho; Hyun Kwon Ha; Jae Young Byun; Jae Mun Lee; Chan Joo Kim; Sung Eun Nam-Koong; Joon Mo Lee
Journal:  AJR Am J Roentgenol       Date:  2002-08       Impact factor: 3.959

8.  In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography.

Authors:  D L Francis; A Freeman; D Visvikis; D C Costa; S K Luthra; M Novelli; I Taylor; P J Ell
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

9.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

View more
  3 in total

Review 1.  Imaging of tumor angiogenesis: functional or targeted?

Authors:  Baris Turkbey; Hisataka Kobayashi; Mikako Ogawa; Marcelino Bernardo; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

2.  Imaging response assessment in oncology.

Authors:  S D Curran; A U Muellner; L H Schwartz
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

3.  Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.

Authors:  Qianxin Jia; Junqing Xu; Weifeng Jiang; Minwen Zheng; Mengqi Wei; Jianghao Chen; Ling Wang; Yi Huan
Journal:  Int J Med Sci       Date:  2012-12-28       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.